Langerhans cell histiocytosis

Howarth, Douglas M.; Gilchrist, Gerald S.; Mullan, Brian P.; Wiseman, Gregory A.; Edmonson, John H.; Schomberg, Paula J.

doi:10.1002/(sici)1097-0142(19990515)85:10<2278::aid-cncr25>3.0.co;2-u

Cited by 566 publications

(144 citation statements)

References 65 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Both pulmonary and thyroid involvement with LCH are rare presentations [1,2]. LCH has been found co-occurring with different malignancies [3][4][5]. We report a very rare case of LCH with concomitant pulmonary and thyroid involvement and accompanying invasive papillary thyroid carcinoma (PTC).…”

Section: Introductionsupporting

confidence: 42%

Langerhans Cell Histiocytosis of the Lung and Thyroid, Co-Existing with Papillary Thyroid Cancer

et al. 2009

View full text Add to dashboard Cite

A 24-year-old man presented to our center with a huge goiter compressing his airway. He had a previous diagnosis of Langerhans cell histiocytosis (LCH) of the lung. Core needle biopsy was consistent with histiocytosis. Thyroidectomy was performed. A very invasive mass was encountered at the time of surgery. Histopathology result was consistent with an invasive papillary cancer of thyroid co-occurring with LCH. Although association of LCH with different malignancies has been reported, co-existing invasive papillary thyroid cancer and LCH is a rare combination.

show abstract

Section: Introductionsupporting

confidence: 42%

Langerhans Cell Histiocytosis of the Lung and Thyroid, Co-Existing with Papillary Thyroid Cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

“…3,8,13,[19][20][21] Low-dose radiotherapy is effective for LCH, and is generally used at a dose of 5-25 Gy. 10,13) Chemotherapy is indicated for multifocal or multisystem LCH. Several different regimens have been employed, but the optimal drug combination remains controversial.…”

Section: Discussionmentioning

confidence: 97%

“…10) The frontal, parietal, and temporal bones are frequent sites of involvement in the skull. 10) Manifestations of LCH of the temporal bone include various otologic symptoms. Patients with squama and mastoid involvement, which are the usual sites of H. Suzuki et al…”

Section: Discussionmentioning

confidence: 99%

“…Howarth et al described that three of 188 patients with osseous LCH showed spontaneous regression without treatment. 10) Spontaneous regression of LCH mostly occurred in infants, so careful monitoring may be a possible option as a management policy for infant LCH. In contrast, spontaneous regression has rarely been reported in adult LCH, so such a waiting policy would not be appropriate for adult cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Langerhans Cell Histiocytosis of the Petrous Bone With Sudden Sensorineural Hearing Loss -Case Report-

Suzuki

Nishizawa

Hohchi

et al. 2010

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

A 56-year-old woman with Langerhans cell histiocytosis of the petrous bone presented with sudden onset of sensorineural hearing loss and vertigo without other neurological impairment, mimicking idiopathic sudden sensorineural hearing loss. Differential diagnosis was difficult until neuroimaging demonstrated a lesion of the petrous bone. The patient eventually underwent removal of the lesion via the transpetrosal approach, and received postoperative chemotherapy consisting of vinblastine, methotrexate, 6-mercaptopurine, and prednisolone. Although her hearing did not recover, complete remission was achieved, and the patient is currently free from disease. Physicians need to be aware that patients with sudden onset of hearing loss may have an unexpected and hidden disease which requires neuroimaging and histological examinations for definitive diagnosis and appropriate treatment.

show abstract

“…Patients with localized disease or diseases limited to single organ system have a good prognosis, thus local therapy or close follow-up without therapy would be an appropriate treatment choice. In contrast, multisystem disease with multiple organ involvement carries a poor prognosis requiring therapy with cytotoxic drugs and/or steroids (1)(2)(3). In one report of 101 children with LCH, the overall survival rate was 79% at 1 year and 71% at 5 years, however, in patients with liver or spleen involvement, 1 year survival was 33% and 5 year survival was 25% (4).…”

Section: Introductionmentioning

confidence: 99%

Successful Treatment of Adult Onset Langerhans Cell Histiocytosis with Multi-Drug Combination Therapy

et al. 2011

View full text Add to dashboard Cite

Adult onset Langerhans cell histiocytosis (LCH) is a rare disorder. Its clinical features have been well described in children, however remain poorly defined in adults. Optimal treatment strategy is still under debate. We have encountered two cases of adult onset LCH, which obtained a durable disease control by combination chemotherapy using prednisone, vinblastine and 6-mercaptopurine. Herein, we report their clinical features together with a review of the current literature.

show abstract

Langerhans cell histiocytosis

Cited by 566 publications

References 65 publications

Langerhans Cell Histiocytosis of the Lung and Thyroid, Co-Existing with Papillary Thyroid Cancer

Langerhans Cell Histiocytosis of the Lung and Thyroid, Co-Existing with Papillary Thyroid Cancer

Langerhans Cell Histiocytosis of the Petrous Bone With Sudden Sensorineural Hearing Loss -Case Report-

Successful Treatment of Adult Onset Langerhans Cell Histiocytosis with Multi-Drug Combination Therapy

Contact Info

Product

Resources

About